Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Center, Korea
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically diagnosed stage IV or recurrent breast cancer patients according to American Joint Committee on Cancer (AJCC)
Positive estrogen receptor or Positive progesterone receptor.
Females at least 18 years of age.
Prior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease
Prior hormone therapy less than 2.
No history of Megace medication for recent 28 days
Performance status of 0, 1 and 2 on the ECOG criteria
Clinically measurable disease, defined as bidimensionally measurable lesions with clearly defined margins on x-ray, CT scan, MRI or physical examination. Lesions serving as measurable disease must be at east 1 cm by 1 cm, as defined by x-ray, CT scan, MRI, or physical examination
Bone only or pleural fluid only disease is included as long as evaluation for clinical benefit is possible
Estimated life expectancy of at least 12 weeks
Compliant patient who can be followed-up adequately.
Adequate hematologic (WBC count 3,000/mm3, platelet count 100,000/mm3), hepatic (bilirubin level 1.8 mg/dL, AST, ALT 1.5xULN, albumin 2.5 g/dL), and renal (creatinine concentration 1.5 mg/dL) function.
Informed consent from patient or patient's relative
Childbearing women should use non-hormonal contraceptive method
You may not be if
Active or uncontrolled infection.
Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence).
Clareo Health | Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
